Drs. Altschuler and Wu

Math Matters at the Project ALS CORE

The key to finding better drugs at the Project ALS Therapeutics Core at Columbia (THE CORE) is developing better pre-clinical laboratory models of ALS. A range of models that actually reflect the human disease and capture the complexity of ALS …
/ Read More

Prosetin Receives Orphan Drug Designation

Earlier this month, we reached a big regulatory milestone: Prosetin received Orphan Drug Designation, or orphan status, for the treatment of ALS from the Food and Drug Administration (FDA). Here, we break down what orphan status means, why it’s important, …
/ Read More
ALS Research Lab

Improving Pharmacokinetic Properties of Promising Compounds

In our biweekly webinars, we have described the process of developing Prosetin—the first potential investigational drug to emerge from The Project ALS Therapeutics Core at Columbia (THE CORE)—in detail. A collaborative team led by Drs. Emily Lowry, Pieter Bos, Brent …
/ Read More
ALS Seminar

Researchers Work Together

In 1998, ALS researchers worked mostly in isolation, often even competing against one another. Project ALS transformed this approach, recruiting world-leading scientists from different fields to work on ALS together, meet regularly, and share data openly. Due to this shift, …
/ Read More
ALS Research

We Know More Today

Project ALS was the first organization to use stem cells to model human ALS; this practice is now used worldwide. Project ALS scientists also use patient stem cells to screen for drugs.
/ Read More
ALS Research Lab

Better Therapies in Development

Project ALS forced a culture shift in ALS research; our first and most crucial breakthrough. In 1998, ALS researchers worked mostly in isolation, often even competing against one another. Project ALS transformed this approach, recruiting world-leading scientists from different fields to work on ALS together, meet regularly, and share data openly. Due to this shift, there has been more advancement towards a cure for ALS in the past 20 years than in the previous 100.
/ Read More